Campbell B C, Kelman A W, Hillis W S
Br J Clin Pharmacol. 1985;20 Suppl 1(Suppl 1):55S-61S. doi: 10.1111/j.1365-2125.1985.tb05143.x.
Calcium antagonists reduce myocardial contractility in vitro. Nicardipine is a dihydropyridine derivative with enhanced selectivity for vascular smooth muscle. We have studied the pharmacokinetics and the haemodynamic effects that occur in man following bolus intravenous administration of nicardipine. Ten normotensive male subjects received either nicardipine or placebo i.v., allocated in a randomised double-blind manner, over 60s. Plasma nicardipine concentration, blood pressure, heart rate, and systolic time intervals were measured before dosing and at frequent intervals between 1 and 360 min post dosing. At 160 micrograms kg-1, adequate plasma levels of nicardipine were obtained to permit analysis of individual pharmacokinetic variables, and significant and consistent haemodynamic effects were seen. After injection of nicardipine, systolic BP and the QS2 (measure of total electromechanical systole) and QT intervals were not altered. The changes in BP and heart rate were consistent with arteriolar vasodilatation. The changes in PEP and LVET suggest an increase in cardiac contractility, which is unlikely to be a direct effect of nicardipine on the myocardium but rather a result of afterload reduction. The close correlation of nicardipine plasma level with haemodynamic effect should permit accurate dose titration. The net increase in contractility should allow nicardipine to be administered safely with beta-adrenoceptor blocking drugs.
钙拮抗剂在体外可降低心肌收缩力。尼卡地平是一种二氢吡啶衍生物,对血管平滑肌具有更高的选择性。我们研究了静脉推注尼卡地平后人体的药代动力学和血流动力学效应。10名血压正常的男性受试者以随机双盲方式在60秒内静脉注射尼卡地平或安慰剂。在给药前以及给药后1至360分钟内频繁测量血浆尼卡地平浓度、血压、心率和收缩期时间间期。给予160微克/千克剂量时,可获得足够的血浆尼卡地平水平以分析个体药代动力学变量,并观察到显著且一致的血流动力学效应。注射尼卡地平后,收缩压、QS2(总电机械收缩期的测量值)和QT间期未发生改变。血压和心率的变化与小动脉血管舒张一致。PEP和LVET的变化表明心脏收缩力增加,这不太可能是尼卡地平对心肌的直接作用,而是后负荷降低的结果。尼卡地平血浆水平与血流动力学效应的密切相关性应有助于准确的剂量滴定。收缩力的净增加应使尼卡地平能够与β肾上腺素能受体阻断药物安全联合使用。